Igen Biolab Group
  • Home
  • About us
  • Pipeline
  • Tecnology
  • Press
    • News
    • Press Releases
    • Events
    • Publications
  • Contact
  • English
    • Español
Select Page
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

by Igen BioLab Group | Mar 3, 2022 | News, Publications

Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut...
Designer probiotic treatment for cancer immunotherapy

Designer probiotic treatment for cancer immunotherapy

by Igen BioLab Group | Feb 25, 2020 | News, Publications

Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of patients and can lead to a multitude of toxicities, suggesting the need for more targeted delivery systems. Because of their preferential colonization of tumors, microbes are a...
Gut bacteria help control healthy muscle contraction in the colon

Gut bacteria help control healthy muscle contraction in the colon

by Igen BioLab Group | Feb 18, 2020 | News, Publications

Micro-organisms in the gut support healthy digestion by helping nerve cells within the intestine to regulate the contraction and relaxation of the muscle wall of the colon, according to new research from the Crick and Bern University. The study, published in Nature,...
Prebiotics help mice fight melanoma by activating anti-tumor immunity

Prebiotics help mice fight melanoma by activating anti-tumor immunity

by Igen BioLab Group | Feb 12, 2020 | News, Publications

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two prebiotics, mucin and inulin, slowed the growth of melanoma in mice by boosting the immune system’s ability to fight cancer.  In contrast to probiotics, which are live...
Manipulating the Human Microbiome to Manage Disease

Manipulating the Human Microbiome to Manage Disease

by Igen BioLab Group | Jan 14, 2020 | News, Publications

More than a decade after the launch of the Human Microbiome Project, research in this field has grown exponentially, with studies associating microbial states or species with disorders including novel infectious etiologies and complex human disease. Scientists are...
« Older Entries

Recent Posts

  • Distinct respiratory microbiota associates with lung cancer clinicopathological characteristics
  • MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
  • Intratumor microbiota: a novel tumor component
  • Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
  • The interplay between the intratumoural microbiome, the type of cancer inflammation and the response to immunotherapy
  • LEGAL NOTICE
  • PRIVACY AND DATA PROTECTION
  • Cookie policy
  • Facebook
  • Twitter
  • Instagram
  • RSS
Design by loComunicas

This website uses its own and third-party cookies in order to analyze the traffic generated for statistical purposes.

You can accept all cookies by clicking "Accept", reject all of them by clicking "Deny" or configure them by clicking "Settings".

For more information on how this site uses cookies and related technologies, you can read our Policy on Cookies

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly necessary cookies

Strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

If you deactivate this cookie, we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Please activate the strictly necessary cookies first so that we can save your preferences!

Cookies policy

More information about our cookie policy